1[1]William CK.Levodopa in the treatment of Parkinsons disease[J].Neurology,2000,55(supp14):2.
2[2]William CK,Miguel GR.Mechamism of action of dopaminergic agents in Parkinsons dosease[J].Neurology,1998,50(supp16):11.
3[3]Chase T,Oh JD.Striatal mechanisms and pathologies of parkinsonian signs and motor complications[J].Ann Neurol,2000,47(supp11):122.
4[4]Mouradian MN,Juncos JL,Fabbrini G,et al.Motor fluctuations in Parkinsons disease:pathogenic and therapeutic studies[J].Ann Neurol,1987,22:475.
5[5]Clemens JA,Fuller RW,Felton SY,et al.Neuroprotection.In:Agid Y ed.Current trends in the treatment of Parkinson disease[C].London:John Libery,1992.69.
6[6]Jenner P.The rationale for the use of dopamine agonist in Parkinsons disease[J].Neurology,1995,45(supp13):6.
7[7]Rabasseda X.Persperctives in the treatment of Parkinsons disease:COMT inhibitors open up new treatment strategies[J].Drugs of Today,1999,35(9):701.
8[8]Cohen G,Pasik P,Yahk MD.Parglline and deprenyl prevent the neurotoxicity of l-methl-4-phenyl-1,2,3,6-tetrahydropyridine(MPTP) inmonkeys[J].Eur Pharmacol,1984,106:209.
9[9]Schneider JS,Roeltgen DP,Mancall EL,et al.Parkinsons disease,Improve function with GM1 gan-glioside treatment in a randomized placebo-controlled study[J].Neurology,1998,50:1630.
